CClinicalTrials.gg
Enrolling by invitationNCT05727852Updated Jul 30, 2024

Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases

An observational study in Chronic Respiratory Diseases, Cystic Fibrosis and Lymphangioleiomyomatosis, sponsored by I.M. Sechenov First Moscow State Medical University. Enrolling by invitation at 1 site in Russian Federation. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by I.M. Sechenov First Moscow State Medical University · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Cross-sectional
Enrollment
400
Ages
18 Years and older
Sex
All
01

Study summary

Assessment of cardiovascular disorders using echocardiography and arterial stiffness; comparative noninvasive assessment of volatile organic compound (eVOC) exhale breath patterns in patients with different chronic respiratory diseases with age and gender-matched healthy adults in order to identify a disease-specific exhaled eVOCs profiles and markers of respiratory and cardiovascular disorders.

Read the detailed description

Evaluating of eVOCs profiles by proton mass spectrometry with a time-of-flight (PTR-TOF) in patients with different chronic respiratory diseases is of great interest for assessing the prognosis and development of severe ventilation and cardiovascular disorders.

The aim of our study is to determine the diagnostic significance of PTR-TOF analysis in patients with chronic respiratory diseases and to identify specific eVOC markers of a severe ventilation and cardiovascular disorders in patients with different chronic respiratory diseases.

02

Conditions studied

  • Chronic Respiratory Diseases
  • Cystic Fibrosis
  • Lymphangioleiomyomatosis
  • Hypersensitivity Pneumonitis
  • Interstitial Lung Diseases
  • COPD
  • Bronchial Asthma

Keywords

  • Proton-transfer reaction mass spectrometry (PTR-TOF-MS)
  • Exhaled volatile organic compounds (eVOCs)
  • Endothelial function
  • Arterial stiffness
  • Cardiovascular disorders
  • Ventilation disorders
  • Gas exchange disorders
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population consists of all males and females over 18 years old in the community according to inclusion, non-inclusion, and exclusion criteria.

Inclusion criteria

  1. Written informed consent to participate in the study;
  2. Age 18 and over;
  3. Clinical diagnosis of one of chronic respiratory diseases (COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis or other interstitial lung disease).

Exclusion criteria

Exclusion Criteria:

  1. Unable to sign informed consent;
  2. Respiratory disease (for controls);
  3. Mental illness (severe dementia, schizophrenia, severe depression, manic-depressive psychosis);
  4. Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism within the last 3 months;
  5. Oncology;
  6. Previous lung transplantation (for patients with respiratory diseases);
  7. Diseases and conditions that can change the ECG picture and complicate the analysis of the ECG (conduction disturbance, pacemaker);
  8. Inability to use a heart monitor (congenital developmental anomalies, traumatic amputation of the upper limbs, essential tremor, Parkinson's disease);
  9. Pregnancy.
04

Study design

Observational model
Case-crossover
Time perspective
Cross-sectional
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Experimental: patients with chronic respiratory diseases

    Included patients, aged ≥ 18 years, with chronic respiratory diseases: COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis and other interstitial lung diseases. Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark"; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of electrocardiogram (ECG), phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs. Interventions: Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor "CardioQvark"; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N.

    Diagnostic Test: Breath test using the Compact PTR-TOF-MS · Diagnostic Test: Portable cardiac monitor "CardioQvark" · Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N

  • Active Comparator: Control

    Included subjects, aged ≥ 18 years. Intervention: breath analysis using the Compact PTR-MS proton mass spectrometer by Ionicon (Austria); electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark"; assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, phonocardiogram (PCG) and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs. Interventions: Diagnostic Test: Breath analysis using the Compact PTR-MS proton mass spectrometer; Diagnostic Test: Portable cardiac monitor "CardioQvark"; Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N.

    Diagnostic Test: Breath test using the Compact PTR-TOF-MS · Diagnostic Test: Portable cardiac monitor "CardioQvark" · Diagnostic Test: Assessment of arterial stiffness using the VaSera VS-1500N

Interventions

  • Diagnostic testBreath test using the Compact PTR-TOF-MS

    Breath samples will be analyzed with a proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria) to obtain eVOCs profiles listed as ions at various mass-to-charge ratios (m/z).

  • Diagnostic testPortable cardiac monitor "CardioQvark"

    Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor "CardioQvark" (Russia, LLC "L Card" , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form.

  • Diagnostic testAssessment of arterial stiffness using the VaSera VS-1500N

    Assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, PCG and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.

05

What researchers measure

Primary outcomes

  1. Molecular composition of exhaled breath analysed by proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria)

    Exhaled volatile organic compounds (eVOCs) profiles listed as ions at various mass-to-charge ratios (m/z)

    Time frame: up to 3 years

  2. Results of recording an electrocardiogram (ECG) in one lead with an assessment of the pulse wave

    Pulse wave velocity, augmentation index, pulse wave type (A, B or C) analysed by a portable cardiac monitor "CardioQvark"

    Time frame: up to 3 years

  3. Indicators of arterial stiffness

    Cardio-ankle vascular index and ankle-brachial index analysed with using the VaSera VS-1500N

    Time frame: up to 3 years

Secondary outcomes

  1. Composite of clinical records

    Clinical data are assessed via questionaire according to the Modified Medical Research Council (mMRC) Dyspnea Scale (scale points: 0 scores - the best outcome, 4 scores - the worst outcome) and Borg Dyspnea scale (scale points: 1 score - the best outcome, 10 scores - thr worst outcome), Standard examination of respiratory function (spirometry: FVC, FEV1, FEV1/FVC, FEF75 - % of predicted, absolute value, z-score; body plethysmography: TLC, RV, VC - % of predicted, absolute value, z-score; diffusion test: DLCO, DLCO/VA - % of predicted, absolute value, z-score), echocardiography, CT scan of the chest, if necessary, sputum culture results

    Time frame: up to 3 years

06

Study locations

1 site
  • I.M. Sechenov First Moscow State Medical University (Sechenov University), Center "Digital biodesign and personalized healthcare"
    Moscow, 119991, Russian Federation
07

Registry details

Key details

Study ID
NCT05727852
Lead sponsor
I.M. Sechenov First Moscow State Medical University
Responsible party
Sponsor
First posted
Feb 14, 2023
Start date
Jan 30, 2023
Primary completion
Jan 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 30, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion